GP
ABMD

Geneva Partners’s Abiomed Inc ABMD Stock Holding History

Geneva Partners’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,755
Closed -$464K – 95
2017
Q3 		$464K Buy
+2,755
New +$417K 0.37% 69

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geneva Partners's ABMD Position: Q4 2017 in Review

Geneva Partners sold out of Abiomed Inc (ABMD) in Q4 2017, closing a stake of 2,755 shares — an estimated $464K sold.

Geneva Partners first reported a position in ABMD in Q3 2017 and held it in 1 quarter. The position peaked at $464K in Q3 2017. 361 funds tracked by Wall St. Rank hold ABMD as of Q4 2017.

  • Geneva Partners reported no remaining Abiomed Inc position as of Q4 2017 after selling out during the quarter.
  • Geneva Partners sold 2,755 Abiomed Inc shares in Q4 2017, an estimated $464K.
  • Geneva Partners first reported a position in Abiomed Inc in Q3 2017 and held it in 1 quarter.
  • Geneva Partners's Abiomed Inc position peaked at $464K in Q3 2017.
  • 361 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2017.

Based on Geneva Partners's 13F filing for Q4 2017, filed 8 Feb 2018.